Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2026 financial and ...

OCT-980 is designed to stabilize misfolded rhodopsin and restore proper cellular trafficking. By directly targeting the ...

J.P. Morgan, Morgan Stanley, TD Cowen and UBS Investment Bank are acting as lead book-running managers for the offering.

Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of ...

The 2026 honorees include innovative companies whose treatments have significantly improved rare disease patient outcomes, ...

Compact system offers research laboratories a time-saving and cost-efficient way to automate work still done by hand ...

Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment ...

Metastasis—the spread of cancer from a primary tumor to other parts of the body—causes most cancer-related deaths. But how ...

COPENHAGEN, Denmark; September 24, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to ...

Elephas Biosciences Corporation, developer of a functional precision medicine platform for oncology therapy response ...

Taro-Methylphenidate ER is the first and only bioequivalent to Concerta® with an osmotic delivery system indicated for the ...

Dr. Gwathmey comes to NYU Langone from the University of Virginia Health System where, as an orthopedic surgeon in 2013, he ...